{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:10:58Z","timestamp":1786122658768,"version":"build-2736575974"},"reference-count":34,"publisher":"Media Sphere Publishing House","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:p>Objective. To evaluate the effectiveness of Cytoflavin in conjunction with standard therapy compared to standard therapy alone in patients presenting during the acute phase of ischemic stroke (IS). Material and methods. A systematic literature review and meta-analysis were conducted to assess the efficacy of Cytoflavin (containing inosine, nicotinamide, riboflavin, and succinic acid; STPF POLYSAN, Ltd., Russia) in adult patients diagnosed with IS. The analysis encompassed both randomized and non-randomized controlled trials, assessing outcomes such as hospital mortality, neurological deficit (measured using the National Institutes of Health Stroke Scale, NIHSS), and functional outcomes (assessed using the modified Rankin Scale and Barthel Index). Results. The incorporation of Cytoflavin into standard treatment protocols was associated with a statistically significant reduction in mortality rates when compared to standard therapy alone (hazard ratio [HR]=0.53; 95% confidence interval [CI] 0.37; 0.76, p&lt;0.001). Furthermore, there was a notable improvement in the regression of neurological deficits during the acute phase of IS, as evidenced by higher NIHSS scores and better functional outcomes (Barthel Index) in patients receiving Cytoflavin. Conclusion. The findings from this systematic review and meta-analysis indicate that the addition of Cytoflavin to standard therapy for ischemic stroke is associated with more favorable clinical outcomes, including decreased mortality, diminished neurological impairment, and improved functional outcomes at the end of the IS acute phase. It is imperative to consider the high heterogeneity in the functional scales data across studies when interpreting these effects.<\/jats:p>","DOI":"10.17116\/jnevro202612607175","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:16:52Z","timestamp":1786101412000},"page":"75","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of the efficacy of Cytoflavin in the acute phase of ischemic stroke: a systematic review and meta-analysis"],"prefix":"10.17116","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-2127","authenticated-orcid":false,"given":"A.M.","family":"Alasheev","sequence":"first","affiliation":[{"name":"Sverdlovsk Regional Clinical Hospital No. 1","place":["Yekaterinburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-9421","authenticated-orcid":false,"given":"T.V.","family":"Kharitonova","sequence":"additional","affiliation":[{"name":"I.P. Pavlov First State Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-0762","authenticated-orcid":false,"given":"N.A.","family":"Shamalov","sequence":"additional","affiliation":[{"name":"Federal Center for Brain and Neurotechnology","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6484-286X","authenticated-orcid":false,"given":"S.N.","family":"Yanishevskiy","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-2346","authenticated-orcid":false,"given":"D.R.","family":"Khasanova","sequence":"additional","affiliation":[{"name":"Kazan State Medical University","place":["Kazan, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-4823","authenticated-orcid":false,"given":"N.A.","family":"Marskaya","sequence":"additional","affiliation":[{"name":"Federal Center for Brain and Neurotechnology","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4292-4258","authenticated-orcid":false,"given":"I.A.","family":"Voznuk","sequence":"additional","affiliation":[{"name":"I.P. Pavlov First State Medical University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202612607175-1","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20231230825"},{"key":"key-10.17116\/jnevro202612607175-2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00252-0"},{"key":"key-10.17116\/jnevro202612607175-3","unstructured":"Samsonova NA, Karpova MA, Moskvicheva MG. Clinical and expert characteristics of patients with stroke newly recognized as disabled. Medico-Pharmaceutical Journal \u201cPulse\u201d. 2016;18:35-41. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-4","unstructured":"Plotnikova OA, Mavlikaeva YuA. Analysis of disability in the adult population of Perm Krai due to stroke. Problems of Social Hygiene, Healthcare and History of Medicine. 2014;17-19. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-5","doi-asserted-by":"publisher","DOI":"10.29296\/25877305-2023-10-02"},{"key":"key-10.17116\/jnevro202612607175-6","doi-asserted-by":"crossref","unstructured":"Tolpygina SN, Zagrebelny AV, Chernysheva MI, et al. Long-term survival of patients with different types of acute cerebrovascular disorders according to the outpatient part of the REGION-M registry. Cardiovascular Therapy and Prevention. 2022;21:209-215. (In Russ.)","DOI":"10.15829\/1728-8800-2022-3447"},{"key":"key-10.17116\/jnevro202612607175-7","unstructured":"Clinical guidelines of the Ministry of Health of the Russian Federation. Ischemic stroke and transient ischemic attack. Accessed Mar 01, 2026. (In Russ.). https:\/\/cr.minzdrav.gov.ru\/preview-cr\/814_1"},{"key":"key-10.17116\/jnevro202612607175-8","unstructured":"EAEU Register of medicinal products and SmPCs. Cytoflavin. Accessed 31 Jan 2026. (In Russ.). https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC"},{"key":"key-10.17116\/jnevro202612607175-9","unstructured":"Shabanov PD. Succinate-containing neuroprotectors. Poliklinika. 2014;9(2): 32-34. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-10","unstructured":"Kovalenko AL, Petrov AYu, Romantsov MG. Mechanism of action and pharmacokinetics of the metabolic composition Cytoflavin. Advances in Modern Natural Science. 2002;34:47-48. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-11","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Accessed 8 Apr 2025.  https:\/\/training.cochrane.org\/handbook\/current"},{"key":"key-10.17116\/jnevro202612607175-12","unstructured":"Risk of bias tools \u2014 robvis (visualization tool). Accessed September 20, 2024.  https:\/\/www.riskofbias.info\/welcome\/robvis-visualization-tool"},{"key":"key-10.17116\/jnevro202612607175-13","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201611612144-47"},{"key":"key-10.17116\/jnevro202612607175-14","unstructured":"Rumyantseva SA, Kuznetsov OR, Evseev VN, et al. Energy correction with Cytoflavin in the acute phase of stroke. Intensive Care Bulletin. 2005;3:23-26. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-15","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201611612144-47"},{"key":"key-10.17116\/jnevro202612607175-16","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2026126031116"},{"key":"key-10.17116\/jnevro202612607175-17","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202312308175"},{"key":"key-10.17116\/jnevro202612607175-18","unstructured":"Nguyen MH, Dang PD, Nguyen TH, et al. Efficiency and Safety Evaluation of Cytoflavin in Patients with Acute Ischemic Stroke. (In Russ.). Accessed July 08, 2026.  https:\/\/medi.ru\/info\/28888"},{"key":"key-10.17116\/jnevro202612607175-19","doi-asserted-by":"publisher","DOI":"10.31550\/1727-2378-2019-161-6-23-26"},{"key":"key-10.17116\/jnevro202612607175-20","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202412410122"},{"key":"key-10.17116\/jnevro202612607175-21","unstructured":"Malkova AA, Polyanskikh YuV, Vakhrusheva AT. Evaluation of the efficacy of Ceraxon, Cytoflavin and Cerebrolysin in the treatment of the acute phase of ischemic stroke. Avicenna. 2018;23:8-10. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-22","unstructured":"Fedin AI, Rumyantseva SA, Piradov MA, et al. Efficacy of the neurometabolic protector Cytoflavin in cerebral infarction. Bulletin of I.I. Mechnikov Saint Petersburg State Medical Academy. 2005;6:13-20"},{"key":"key-10.17116\/jnevro202612607175-23","unstructured":"Romantsov M, Kovalenko A. Improving the efficacy of ischemic stroke therapy. Vrach (The Doctor). 2005;14:45-7. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-24","unstructured":"Odinak MM, Skvortsova VI, Voznyuk IA, et al. Evaluation of the efficacy of Cytoflavin in patients during the acute phase of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(12):29-36. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-25","doi-asserted-by":"publisher","DOI":"10.1007\/s11055-011-9496-4"},{"key":"key-10.17116\/jnevro202612607175-26","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20151158145-52"},{"key":"key-10.17116\/jnevro202612607175-27","doi-asserted-by":"publisher","DOI":"10.30906\/0869-2092-2015-78-1-21-26"},{"key":"key-10.17116\/jnevro202612607175-28","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20161163125-28"},{"key":"key-10.17116\/jnevro202612607175-29","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171172164-67"},{"key":"key-10.17116\/jnevro202612607175-30","unstructured":"Fedin AI, Rumyantseva SA, Kuznetsov OR, et al. Evaluation of the efficacy of therapy with the energy corrector Cytoflavin in the acute phase of ischemic stroke. Nervous Diseases. 2004;12(7):27-32. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-31","unstructured":"Romantsov MG, Kovalenko AL. Neurometabolic protection in cerebral infarction (based on a multicenter randomized study). Fundamental Research. 2005;11(7):29-33. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-32","unstructured":"Rumyantseva SA, Romantsov MG. Efficacy of Cytoflavin in the treatment of acute cerebrovascular accident. Bulletin of I.I. Mechnikov Saint Petersburg State Medical Academy. 2004;5:129-32. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-33","unstructured":"Shestakov VV, Kostenkova NV, Kichigina EV, et al. Larikova TN, Starikova NL. Clinical efficacy of Cytoflavin use in the comprehensive treatment of patients in the acute stage of ischemic stroke. Clinical Medicine. 2011; 89(5):38-40. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607175-34","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171173128-39"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:17:10Z","timestamp":1786101430000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2026\/7\/1199772982026071075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8,7]]}},"alternative-id":["10.17116\/jnevro202612607175"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202612607175","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}